Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients
| Autor: | Yunxiao Xu, Guangsen Zhang, Wenli Zheng, Min-fei Pei, Jian-kai Shen, Chong-Wen Dai |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Adolescent Combination therapy medicine.drug_class Retinoic acid Tretinoin Arsenicals chemistry.chemical_compound Arsenic Trioxide Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Clinical efficacy Retinoid Arsenic trioxide Aged Response rate (survey) business.industry Oxides Hematology Middle Aged Thalidomide Clinical trial Treatment Outcome chemistry Myelodysplastic Syndromes Female business medicine.drug |
| Zdroj: | Leukemia Research. 32:251-254 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2007.05.025 |
| Popis: | Objective To evaluate the clinical efficacy and safety of arsenic trioxide, retinoic acid and thalidomide combination therapy in higher risk MDS. Methods Twenty-one patients diagnosed with higher risk MDS were administered 10 mg/day arsenic trioxide intravenously for 10 days, 40 mg/day retinoic acid orally for 2 weeks and 100 mg/day thalidomide orally for 4 weeks per cycle. Results After at least two treatment cycles, 10 patients showed hematologic responses. One achieved CR, one achieved PR, three patients achieved major hematological improvements. The efficacy rate was 24% (5/21), and the response rate was 48% (10/21). The schedule was tolerated well by all patients and toxicities were moderate and reversible. Conclusion The combination of arsenic trioxide, retinoic acid and thalidomide could have therapeutic benefit in higher risk MDS with safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect